Percheron Therapeutics LimitedASX: PER

Topline Six-Month Results From Phase IIb Study of Avicursen

· Issued by Percheron Therapeutics Limited

Filed with ASX · · 3 pages · English

Summary by 6ix AI

Percheron Therapeutics Limited has announced the topline six-month results from its Phase IIb study of avicursen in non-ambulant boys with Duchenne muscular dystrophy. The trial did not meet its primary endpoint, showing no statistically significant differences in efficacy compared to placebo. The company has decided to terminate the study due to these results and will conduct a strategic review of the avicursen program in the coming months. The drug was reported to be safe and well-tolerated, with mild to moderate injection site reactions being the most common adverse event.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Percheron Therapeutics Limited on 6ix

Story so far

Earlier from Percheron Therapeutics

Later from Percheron Therapeutics

All Percheron Therapeutics news releases